Jagsonpal Pharmaceuticals Limited Stock Price Today (NSE: JAGSNPHARM)
Fundamental Score
Jagsonpal Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Jagsonpal Pharmaceuticals Limited share price today is ₹228.28, up +1.08% on NSE/BSE as of 16 September 2026. Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.50K (Cr). The 52-week high for JAGSNPHARM share price is ₹264.50 and the 52-week low is ₹155.00. At a P/E ratio of 33.57x, JAGSNPHARM is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 16.69% and a debt-to-equity ratio of 0.00.
Jagsonpal Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Jagsonpal Pharmaceuticals Limited share price chart: 1.04% return over the past month. 52-week high ₹264.50, 52-week low ₹155.00.
Jagsonpal Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹224.70 | ₹230.95 | ₹217.81 | ₹228.28 | 56.47K (Cr) | |
| ₹234.60 | ₹234.99 | ₹223.16 | ₹225.83 | 57.01K (Cr) | |
| ₹229.21 | ₹234.60 | ₹228.01 | ₹232.89 | 51.42K (Cr) | |
| ₹235.39 | ₹239.17 | ₹231.11 | ₹232.99 | 47.33K (Cr) | |
| ₹236.00 | ₹239.38 | ₹229.02 | ₹235.39 | 69.84K (Cr) | |
| ₹239.51 | ₹241.33 | ₹236.10 | ₹237.72 | 59.50K (Cr) | |
| ₹242.06 | ₹247.96 | ₹237.20 | ₹239.06 | 59.70K (Cr) | |
| ₹242.00 | ₹243.18 | ₹238.81 | ₹242.06 | 96.23K (Cr) | |
| ₹237.40 | ₹249.57 | ₹237.01 | ₹243.02 | 3.00L (Cr) | |
| ₹239.49 | ₹239.55 | ₹235.50 | ₹237.03 | 58.88K (Cr) |
Jagsonpal Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹241.00 | ₹249.57 | ₹217.81 | ₹228.28 | -5.28% | |
| ₹228.50 | ₹248.00 | ₹223.00 | ₹240.84 | +5.40% | |
| ₹240.00 | ₹263.70 | ₹214.24 | ₹230.80 | -3.83% | |
| ₹207.90 | ₹264.50 | ₹197.25 | ₹238.10 | +14.53% | |
| ₹206.37 | ₹225.12 | ₹194.61 | ₹206.60 | +0.11% | |
| ₹185.80 | ₹213.70 | ₹184.00 | ₹210.37 | +13.22% | |
| ₹165.30 | ₹201.50 | ₹157.55 | ₹184.03 | +11.33% | |
| ₹169.00 | ₹188.00 | ₹163.70 | ₹168.67 | -0.20% | |
| ₹193.57 | ₹195.00 | ₹155.00 | ₹168.82 | -12.79% | |
| ₹215.52 | ₹222.00 | ₹190.10 | ₹192.61 | -10.63% | |
| ₹224.10 | ₹230.00 | ₹195.00 | ₹215.52 | -3.83% | |
| ₹219.27 | ₹225.49 | ₹211.00 | ₹222.84 | +1.63% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Jagsonpal Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jagsonpal Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JAGSNPHARM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (16.69%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.65%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (16.62%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (22.18%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Profit Growth Track Record (20.36% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (56.95x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 6.22)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹188.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (67.54%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
High Price-to-Book Ratio (6.32x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-0.34% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Limited Institutional Interest (FII+DII: 2.92%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Jagsonpal Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Jagsonpal Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Jagsonpal Pharmaceuticals LimitedJagsonpal Pharm...Selected✓ JAGSNPHARM • 507789 | 68.3/100 | ₹228.28₹228 | ₹1503.00₹1503.00 | 33.57Average 33.6 Average | 16.69%Good 16.69% Good | 21.65%Excellent 21.65% Excellent | 0.00Excellent 0.0 Excellent | 20.36%Excellent 20.36% Excellent | 8.85%Good 8.85% Good | 1.11% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Jagsonpal Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for JAGSNPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.22 | ₹192.61 | 23.4x |
| FY 2024 | ₹3.39 | ₹244.34 | 72.1x |
| FY 2023 | ₹4.08 | ₹155.56 | 38.1x |
| FY 2022 | ₹2.88 | ₹149.10 | 51.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Jagsonpal Pharmaceuticals Limited Dividend History
Annual cash dividends paid by JAGSNPHARM — dividend yield 1.11%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹13.23 Cr |
| FY 2024 | ₹13.10 Cr |
| FY 2022 | ₹10.48 Cr |
| FY 2021 | ₹2.62 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Jagsonpal Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for JAGSNPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
8.76%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
22.18%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.85%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
20.36%
Compounded annual net profit growth over 5 years
Jagsonpal Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for JAGSNPHARM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Jagsonpal Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Jagsonpal Pharmaceuticals Limited
About JAGSNPHARM (Jagsonpal Pharmaceuticals Limited)
Jagsonpal Pharmaceuticals Ltd is a distinguished pharmaceutical company that has etched its mark on the healthcare landscape. With a steadfast commitment to innovation and quality,... Jagsonpal specializes in the development, production, and distribution of a diverse range of pharmaceutical products. The company's extensive portfolio encompasses formulations that cater to various therapeutic areas, addressing critical healthcare needs. Through rigorous research and development efforts, Jagsonpal remains at the forefront of pharmaceutical advancements, ensuring that patients have access to effective and cutting-edge treatments. Their products, known for their efficacy and reliability, are trusted by healthcare professionals and patients alike. The company continually strives to improve patient outcomes and contribute to the overall well-being of society. Driven by a dedication to excellence, Jagsonpal Pharmaceuticals operates with state-of-the-art manufacturing facilities and adheres to stringent quality control measures. This meticulous approach ensures that every product meets the highest industry standards and regulatory requirements. From sourcing premium ingredients to employing advanced manufacturing techniques, Jagsonpal maintains unwavering control over the entire production process. Their focus on quality extends beyond manufacturing, encompassing all aspects of the business, including customer service and ethical practices. This commitment to quality has earned Jagsonpal a strong reputation for integrity and trustworthiness within the pharmaceutical industry. Jagsonpal Pharmaceuticals distinguishes itself through its patient-centric approach, placing the needs and well-being of individuals at the heart of its operations. The company's dedication to improving lives is evident in its focus on developing innovative therapies and making them accessible to those who need them most. Furthermore, Jagsonpal is committed to sustainability and responsible business practices, recognizing the importance of environmental stewardship and ethical conduct. With a strong legacy of pharmaceutical excellence and a forward-looking vision, Jagsonpal Pharmaceuticals is poised to continue making a significant contribution to healthcare for generations to come.
Company Details
Key Leadership
JAGSNPHARM Share Price: Frequently Asked Questions
What is the current share price of Jagsonpal Pharmaceuticals Limited?
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) trades at ₹228.28 on NSE and BSE. Market cap ₹1.50K (Cr). Educational data only.
What is the P/E ratio of Jagsonpal Pharmaceuticals Limited?
Jagsonpal Pharmaceuticals Limited has a P/E of 33.57x vs industry average 34.89x.
What is the Bull Run score for Jagsonpal Pharmaceuticals Limited?
Jagsonpal Pharmaceuticals Limited has a Bull Run score of 68.3/100 based on 25+ financial parameters.
Does Jagsonpal Pharmaceuticals Limited pay dividends?
Jagsonpal Pharmaceuticals Limited has a dividend yield of 1.11%. Past dividends don't guarantee future payments.
What is the ROE of Jagsonpal Pharmaceuticals Limited?
Jagsonpal Pharmaceuticals Limited has ROE of 16.69%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Jagsonpal Pharmaceuticals Limited?
Jagsonpal Pharmaceuticals Limited has debt-to-equity of 0.00.
Is Jagsonpal Pharmaceuticals Limited a good investment?
Bull Run gives Jagsonpal Pharmaceuticals Limited a score of 68.3/100. This is not investment advice — consult a SEBI-registered advisor.